Serum concentrations of Thymidine kinase 1 measured using a novel antibody-based assay in patients with Hodgkin Lymphoma

• Published in: Upsala journal of medical sciences Vol. 126; no. 1; pp. e6119 - 6
• Main Authors: Mattsson Ulfstedt, Johan, Venge, Per, Holmgren, Sofia, Enblad, Gunilla, Eriksson, Staffan, Molin, Daniel
• Format: Journal Article
• Language: English
• Published: Sweden Open Academia 2021; Upsala Medical Society
• Subjects: Antibodies; Biobanks; Biomarkers; Biomarkers, Tumor; Cell cycle; Cell growth; Chemotherapy; Dehydrogenases; Disease; Hemoglobin; Histology; Hodgkin Disease; Hodgkin lymphoma; Humans; Immunologi inom det medicinska området; Immunology in the medical area; Kinases; Lymphocytes; Lymphoma; Medical prognosis; Original; Patients; Plasma; prognostic markers; Proteins; Software; Thymidine Kinase; TK1; Tomography; Tumors; Variables; Thymidine kinase; TK1; prognostic markers; chemotherapy; Hodgkin lymphoma
• ISSN: 0300-9734; 2000-1967; 2000-1967
• DOI: 10.48101/ujms.v126.6119

Thymidine kinase 1 (TK1) is an intracellular protein associated with DNA synthesis, expressed during the G1 phase and remained elevated through the M phase, with a potential as a biomarker for cell proliferation. In this study, we explore the possible use of TK1 in Hodgkin lymphoma (HL). Serum concentrations of TK1 (S-TK1) were measured in 46 newly diagnosed HL patients using prospectively collected biobanked serum samples. The samples were analyzed using a novel antibody-based TK1 immunosorbent assay (ELISA). The concentrations of S-TK1 were elevated in HL patients compared with healthy controls (median 0.32 μg/L vs. 0.24 μg/L, = 0.003). A further increase in S-TK1 was observed during the treatment. The S-TK1 concentrations were higher in patients with advanced stage disease, low B-Hb, elevated P-LD and in those with B-symptoms. A high ESR correlated with low S-TK1. The study results suggest that S-TK1, measured using a novel antibody-based assay, has the potential to be a biomarker in HL. However, while S-TK1 levels are elevated at baseline compared with healthy controls, a limited number of patients and comparatively short follow-up time render reliable conclusions difficult.